✦ LIBER ✦

High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study

✍ Scribed by L. Mannone; C. Gardin; M. C. Quarre; J. F. Bernard; D. Vassilieff; L. Ades; S. Park; S. Vaultier; F. Hamza; M. O. Beyne-rauzy; S. Cheze; S. Giraudier; P. Agape; L. Legros; L. Voillat; F. Dreyfus; P. Fenaux; for the Groupe Francais des Myelodysplasies (GFM)

Book ID: 108673740
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 91 KB
Volume: 133
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2006.06070.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Darbepoetin alpha for the treatment of a

Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes

✍ Pellegrino Musto; Francesco Lanza; Enrico Balleari; Alberto Grossi; Antonietta F 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB

A phase II dose finding study of darbepo

A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment

✍ Z. M. Younossi; F. H. Nader; C. Bai; R. Sjogren; J. P. Ong; R. Collantes; M. Sjo 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 165 KB

A phase-II trial of alltransretinoic aci

A phase-II trial of alltransretinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes

✍ A. Venditti; A. Tamburini; F. Buccisano; M. T. Scimò; G. Del Poeta; L. Maurillo; 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 78 KB

The evaluation of low-dose cytarabine in

The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: A phase-III intergroup study

✍ K. B. Miller; K. Kyungmann; F. S. Morrison; J. N. Winter; J. M. Bennett; R. S. N 📂 Article 📅 1992 🏛 Springer 🌐 English ⚖ 744 KB

The evaluation of low-dose cytarabine in

The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study

✍ K. B. Miller; K. Kyungmann; F. S. Morrison; J. N. Winter; J. M. Bennett; R. S. N 📂 Article 📅 1993 🏛 Springer 🌐 English ⚖ 23 KB

A randomized study of 2 dose levels of i

A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome

✍ Stefan Faderl; Guillermo Garcia-Manero; Elias Jabbour; Farhad Ravandi; Gautam Bo 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 181 KB 👁 1 views

## Abstract ## BACKGROUND: Clofarabine is a nucleoside analog with activity in myeloid malignancies. Experience in myelodysplastic syndrome (MDS) is limited. ## METHODS: The goal of this study was to evaluate the activity and safety of 2 different doses (15 mg/m^2^ vs 30 mg/m^2^ daily × 5 days)